Virginia E. Kwitkowski

Author

United States Food and Drug Administration

Also Known As

V Kwitkowski, V. E. Kwitkowski, Virginia E. Kwitkowski, Virginia Elaine Kwitkowski, Virginia Kwitkowski

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research National Institutes of Health National Cancer Institute Center for Cancer Research

About

Virginia E. Kwitkowski is an author at United States Food and Drug Administration specializing in medicine, immunology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	657
2	Health Sciences	5	5	224
3	Immunology	5	5	169
4	Pharmacology	4	4	208
5	Pathology	2	2	370

Virginia E. Kwitkowski

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski, Journal of Clinical Oncology	2008	336
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma Virginia E. Kwitkowski, Tatiana M. Prowell, Amna Ibrahim, The Oncologist	2010	240
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski, Clinical Cancer Research Lymphoid NeoplasiaTranslational MedicineHodgkin LymphomaU.s. FoodMedicine	2012	207
PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) Ethan Basch, Bryce B. Reeve, Charles S. Cleeland, Value in Health Pcn122 DevelopmentThe Patient-reported VersionAdverse EventPatient SafetyDiagnosis	2010	163
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer Edwin M. Posadas, Meghan S. Liel, Virginia E. Kwitkowski, Cancer	2007	143
U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia Firoozeh Alvandi, Virginia E. Kwitkowski, Chia‐Wen Ko, The Oncologist PharmacotherapyPre-clinical PharmacologyMyeloid NeoplasiaHematological MalignancyTranslational Medicine	2013	96
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the <i>BRAF</i>V600 Mutation Patricia O’Neal, Virginia E. Kwitkowski, Lola Luo, The Oncologist	2018	76
A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer Edwin M. Posadas, Virginia E. Kwitkowski, Herbert L. Kotz, Cancer	2007	60
Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski, Journal of Clinical Oncology OncologyAngiogenesisCohort 2MedicineImmunology	2006	42
U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia Hyon-Zu Lee, Barry W. Miller, Virginia E. Kwitkowski, Clinical Cancer Research ImmunologyFda ApprovalPharmacotherapyImmunotherapyDrug Resistance	2014	41

Page 1